Skip to main
ENOV

Enovis Corp (ENOV) Stock Forecast & Price Target

Enovis Corp (ENOV) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enovis is a medical technology company that operates in two segments with limited exposure to bone stimulation, positioning it well for the FDA's recent changes to the classification. With a strong financial profile and a diverse portfolio of products, the company is expected to continue its growth through strategic M&A and new product launches, positioning it for success in the estimated billion-dollar market for orthopedic products. While facing risks related to competition, market conditions, and debt, other successful companies in the industry also have a favorable outlook, including Stryker Corporation and Shoulder Innovations, with steady growth and multiple.

Bears say

Enovis is a medical technology company that operates in highly competitive markets against larger competitors, limiting its ability to withstand economic downturns and pricing pressures that could impact its growth and profitability. While the company shows potential for growth in its Reconstructive segment, the recent divestiture of its Prevention & Recovery segment and potential risks associated with M&A integration could cause disruptions and limit the company's performance in the near term. Additionally, the company's exposure to tariff and manufacturing risks could affect its financials and margins. Current valuation levels may not accurately reflect the company's long-term growth potential, but the company still faces execution risks with its strategic initiatives.

Enovis Corp (ENOV) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enovis Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enovis Corp (ENOV) Forecast

Analysts have given Enovis Corp (ENOV) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Enovis Corp (ENOV) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enovis Corp (ENOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.